CONy 2022 | The 5-2-1 screening criteria and other advances in Parkinson’s disease

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, provides an overview of technological and screening updates in Parkinson’s disease. With the advent of wearable technology that can measure biological processes, wearable gadgets that can monitor gait and balance in patients may have clinical applications. Prof. Antonini additionally highlights the need for a more unified criteria to diagnose Parkinson’s disease and suggests the 5-2-1 screening criteria, which involves oral levodopa tablet taken 5 times per day, 2 hours of off time a day and one 1 hour of recorded troublesome dyskinesia a day. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.